Amgen Rallies 10%+ After Hours on Q1 Earnings and Revenue Beats, Plus Well-Received Full-Year Guidance
Amgen Rallies 10%+ After Hours on Q1 Earnings and Revenue Beats, Plus Well-Received Full-Year Guidance
quarterly earnings of $3.96 per share which beat the analyst consensus estimate of $3.87 by 2.33 percent. By Jerry Kronenberg | Moomoo News
作者：傑裏·克羅嫩伯格 | Moomoo 新聞
$Amgen (AMGN.US)$ rose more than 10% after hours Thursday after the pharma giant beat analyst estimates for Q1 earnings and revenues and guided full-year results to potentially exceed analysts’ forecasts.
$安進 (AMGN.US)$ 週四盤後上漲了10％以上，此前這家制藥巨頭超過了分析師對第一季度收益和收入的預期，並指導全年業績可能超過分析師的預期。
AMGN gained 11.7% to $311 shortly before 5:30 p.m. ET after the firm reported $3.96 in Q1 earnings per share, reportedly beating analysts’ $3.87 consensus forecast.
美國東部時間下午5點30分前不久，AMGN上漲11.7％，至311美元，此前該公司公佈的第一季度每股收益爲3.96美元，據報道超過了分析師的3.87美元。
quarterly earnings of $3.96 per share which beat the analyst consensus estimate of $3.87 by 2.33 percent.
季度每股收益爲3.96美元，比分析師普遍預期的3.87美元高出2.33％。
Sales totaled $7.447 billion, exceeding the $7.436 billion consensus among analysts and rising some 22% from the $6.105 billion Amgen recorded in the same period last year.
總銷售額爲74.47億美元，超過了分析師共識的74.36億美元，較去年同期安進的61.05億美元增長了約22％。
AMGN also guided full-year earnings per share to a range of $19 to $20.20 on $32.5 billion to $33.8 billion in revenues. The range’s upper end would exceed analysts’ reported consensus forecast of $19.53 in full-year EPS and $32.9 billion of revenues.
AMGN還將全年每股收益定在19美元至20.20美元之間，收入爲325億美元至338億美元。該區間的上限將超過分析師報告的共識預測，即全年每股收益19.53美元，收入爲329億美元。
Meanwhile, Amgen reportedly said in its conference call that it’s giving up on developing a pill form of weight-loss drugs that would compete with red-hot Ozempic and Wegovy, which users must inject with a syringe. Amgen rival $NOVO NORDISK A/S (NONOF.US)$ developed Ozempic and Wegovy.
同時，據報道，安進在電話會議上表示，它正在放棄開發一種藥丸形式的減肥藥物，這種藥物將與炙手可熱的Ozempic和Wegovy競爭，使用者必須用注射器注射。安進的競爭對手 $NOVO NORDISK A/S (NONOF.US)$ 開發了 Ozempic 和 Wegovy。
Still, Amgen reportedly said it plans to continue developing its own injectable weight-loss drug to take on those competitors.
儘管如此，據報道，安進表示計劃繼續開發自己的可注射減肥藥物，以對抗這些競爭對手。